Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
64% of IG markets oil positions still short. Couldn’t believe my eyes idiots gonna lose their shirts!! Shows Oil has still got long way to go I’m thinking 120/130 could be possible this year. How much we making with 120 oil?!
How many times can he tip KMK to the same audience? I'm also not convinced ST provides anything more then a short term bounce. The only thing that matters here is Basu actually delivering something that assures the market no more placings!
I believe they where hoping to start drilling Serenity March/April as mentioned by Majid last year on a conference call. Oil price outlook has strengthened significantly since then. Is there something i missed that now makes this timeline unlikely? If drilling was to start March/April what's the absolute latest we think they could announce?
If you mean by "keeping their heads down" they weren't trying their hardest to achieve maximum commercialization that is a kick in the teeth to the share holders who have held for 8+ years suffering huge dilution every 2 years and devastating losses. Remember:
16th Oct 2013 - SP = 51p
Arnab Basu, CEO, commented: "We are delighted with our oversubscribed fundraising. After many years developing the business and our technology, Kromek is ready to begin harvesting value by seizing the opportunities to sell our technology and products into the medical imaging, security screening and nuclear detection markets.
"and the commercial launch of the Covid-19 airborne detector imminent, then I maintain the view the share price could double. Buy."
Would be interested to hear your thought skid35. I do feel a bit more optimistic after reading. There will be major pressure on Basu if he doesn't deliver something regarding Covid detector in first 6 months after he specifically mentioned April.
Investors are materially underestimating trading prospects of Kromek (KMK:14.5p) in what could be a pivotal year for the Sedgefield-based radiation detection technology company that is focused on the medical, security screening and nuclear markets.
Firstly, during our results call, chief executive Arnab Basu revealed that he expects first commercial sales by April for Kromek’s bio-security pathogen detectors which sample air and identify the presence of any biological pathogen including Covid-19. The company is working with the NHS and a major transportation group, both sectors being obvious candidates for deployment on a commercial basis.
Secondly, Canon’s recent US$270m (£199m) acquisition of Redlen Technologies, the only independent commercial producer of Cadmium Zinc Telluride (CZT) detectors globally other than Kromek, is material. House broker Cenkos Securities’ read across implies a valuation of £196m (45p a share) on Kromek’s medical imaging business, or more than three times Kromek’s current market capitalisation.
Moreover, by removing one rival from the market, it means that medical imaging OEMs – Phillips and United Imaging, for instance – that are looking to adopt CZT technology but lack in-house production capacity are now far more reliant on Kromek than previously. Basu notes that three new strategic original equipment manufacturers (OEMs) have placed initial orders with Kromek and “we expect a number of contracts to be signed in 2022 as they look for surety of supply”, adding that “more conversations are ongoing”. They could be very large contracts given that one seven-year medical imaging contract signed with an OEM in 2019 is delivering US$58m of revenue to Kromek over a seven-year contract term.
Basu also revealed the potential to split out the group’s two distinct business units – chemical, biohazard security, radiation and nuclear (CBRN) activities comprise the other one. The fact that the directors have segmented the two operations in the results presentation is telling. The point is that a medical imaging OEM looking for security of CZT supply could be tempted to make a bid for that part of Kromek’s business, which analyst Mike Jeremy at Equity Development values at £225m. He also highlights the undervaluation of the CBRN business, which could generate half of group revenue of £18m in the 2022/23 financial year, and could be worth £54m.
Importantly, with 96 per cent of budgeted annual revenue of £15m covered by orders as well as 60 per cent of the £18m revenue estimate for 2022/23, then the long-awaited move into cash profitability is on the cards. Jeremy predicts £0.6m cash profit in the second half to 30 April 2022 to wipe out the £0.6m first-half loss, and is pencilling in cash profit of £0.75m in 2022/23.
Kromek’s shares have been volatile since my last buy call at 15.75p (‘Backing a tech winner in the fight against Covid-19’, 14 July 2021), but with game-changing orders from medical imaging OEMs likely and
Crikey Pete - Wouldn't be knocking him either if he made me that kind of money. i am incredibly small time compared to you lol!He is a bit dodgy though. Loads up on the quiet then announces to his army of fans he has found the most undervalued share of all time, best thing since sliced bread!! Pretty obvious pattern but if you get in and out at right times clearly big money to be made... congrats!
Correction got my CEO's confused Arnab not Majid. Aqc888 i hope your correct but this has been such a disappointment and shareholders here are treated with such disregard i will continue to be negative until we get a reason not to be.
Majid has performed so poorly as CEO (51p to 15p in 8 years with huge dilution every 2 years while never making a profit) that they get no benefit of doubt and have been written off. Until we get the game changing news we all hoping for we should expect more of the same. Getting ridiculous now Basu give us an update!!